We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,498

Sandoz’s Challenge to Two of AbbVie’s Humira Patents Denied by PTAB
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • February 26 2018

Sandoz’s request for inter partes review (“IPR”) of U.S. Patent Numbers 9,512,216 (“the ’216 patent”) and 8,802,100 (“the ’100 patent”) was denied by

Top 5 PTAB Related Decisions of 2017
  • Ropes & Gray LLP
  • USA
  • February 21 2018

With so much attention being paid to Oil States, it was easy to lose sight of many of the more noteworthy Patent Trial & Appeal Board (PTAB) related

Corporate crime & Investigations Update - 9 February 2018
  • Addleshaw Goddard LLP
  • United Kingdom, European Union
  • February 12 2018

Several former ministers and two former Prime Ministers of Greece have been named in a corruption investigation into Swiss pharmaceutical company

ECJ finds that arrangement between Hoffmann-La Roche and Novartis may restrict competition “by object”
  • Slaughter and May
  • European Union
  • January 31 2018

On 23 January 2018 the European Court of Justice (ECJ) handed down its judgment in Hoffmann-La Roche and Others v AGCM. The ECJ held that it is a

Year in Review: Key Decisions from 2017
  • Baker Botts LLP
  • USA
  • December 22 2017

With the end of the year approaching, we look back on the most important decisions affecting PTAB practice of 2017 and look forward to what is coming

California Supreme Court Recognizes “Innovator Liability”
  • Bradley Arant Boult Cummings LLP
  • USA
  • December 22 2017

Yesterday, the California Supreme Court in T.H. v. Novartis Pharmaceuticals Corp., became the first state high court to recognize the doctrine of

GSK and Novartis are in hot water for mislabelling Voltaren Osteo Gel to charge price premium
  • Cordato Partners
  • Australia
  • December 14 2017

Fresh from its success in the Nurofen Specific Pain products proceedings, the Australian Competition & Consumer Commission (ACCC) is looking for a

Novartis’ former IP chief urges innovative pharma to emulate high-tech patent strategies
  • IAM
  • USA
  • December 8 2017

The former global head of pharma intellectual property at Novartis has told IAM that life sciences companies should consider a more tech-like approach

PTAB Not Always Bound By Previous Court Decisions Regarding Patent Validity
  • Marshall Gerstein & Borun LLP
  • USA
  • December 4 2017

In Novartis AG v. Noven Pharm. Inc., Appeal 2016-1678-1679 (April 2017), Novartis appealed two PTAB decisions holding claims of two patents obvious

SIPO Published the Fifth Case for Public Trail
  • AFD China Intellectual Property Law Office
  • China
  • September 26 2017

On September 15, the Patent Reexamination Board (PRB) under the Staten Intellectual Property Office (SIPO) held an oral hearing for the patent